Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Background: SAR342434 (U100; SAR-Lis; insulin lispro) is a biosimilar/follow-on to insulin lispro (U100; Ly-Lis). Similar pharmacokinetics/pharmacodynamics between the two products has been demonstrated in a hyperinsulinemic euglycemic clamp study. The current study evaluated the safety of SAR-Lis and Ly-Lis when administered by continuous subcutaneous insulin infusion (CSII; insulin pumps). Methods: This was a randomized, open-label, 2 × 4-week, two-arm crossover study in 27 patients with type 1 diabetes mellitus (NCT02603510). The main outcome was the incidence of infusion set occlusions (ISOs), defined as failure to correct hyperglycemia (plasma glucose ≥≥ 300 mg/dl) by 50 mg/dl within 60 minutes by insulin bolus via the pump. Secondary outcomes included intervals between infusion set changes, treatment-emergent adverse events (TEAEs) including infusion site, hypersensitivity reactions and hypoglycemic events, and safety. Results: The number of patients reporting at least one ISO was small: 6/25 patients on SAR-Lis reported 14 ISOs and 4/27 on Ly-Lis reported nine ISOs. The estimated difference in ISO risk for SAR-Lis versus Ly-Lis was 7.9% (95% CI, –1.90 to 17.73). Mean interval between infusion set changes for any reason was similar with SAR-Lis (3.09 days) and Ly-Lis (2.95 days). The event rate (events/patient-month) of any hypoglycemia was similar with SAR-Lis (7.15) and Ly-Lis (7.98), as was the percentage of patients who experienced any TEAE (12.0% and 14.8%). Conclusion: Both SAR-Lis and Ly-Lis were well tolerated by patients using insulin pumps. The results do not suggest a clinically significant difference in the risk of ISO between SAR-Lis and Ly-Lis when used in CSII.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 1×
“Hypoglycemic episodes were categorized based on American Diabetes Association classifications.(10-12) Documented hypoglycemia was defined as PG ≤70 mg/dl and separately as PG <54 mg/dl.”
MethodDefining and Reporting Hypoglycemia in Diabetes
American Diabetes Association Workgroup on Hypoglycemia (2005) · Diabetes Care · doi:10.2337/diacare.28.5.1245 · Cited by 1,146
International Hypoglycaemia Study Group (2017) · Diabetes Care · doi:10.2337/dc16-2215 · Cited by 608
van Bon, A. C., Bode, B. W., Sert-Langeron, C., DeVries, J. H., & Charpentier, G. (2011) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2010.0224 · Cited by 96
Raskin, P., Holcombe, J. H., Tamborlane, W. V., Malone, J. I., Strowig, S., Ahern, J. A., & Lavent, F. (2001) · Journal of Diabetes and its Complications · doi:10.1016/s1056-8727(01)00168-4 · Cited by 71
Cited by
Bionic Pancreas Research Group, Messer, L. H., Buckingham, B. A., Cogen, F., Daniels, M., Forlenza, G., Jafri, R. Z., Mauras, N., Muir, A., Wadwa, R. P., et al. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0201.pub · Cited by 59
Bionic Pancreas Research Group, Beck, R. W., Russell, S. J., Damiano, E. R., El-Khatib, F. H., Ruedy, K. J., Balliro, C., Li, Z., & Calhoun, P. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2022.0167 · Cited by 40
Kanapka, L. G., Lum, J. W., & Beck, R. W. (2022) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2021.0548 · Cited by 35
Clinical utility of the twiist Automated Insulin Delivery System: first study with twiist
Ruiz, A., Mcdonough, A., Snow, K., Bode, B., & Mitri, J. (2026) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2026-006307
Metadata
- Authors
- Thrasher, J., Surks, H., Nowotny, I., Pierre, S., Rotthaeuser, B., Wernicke-Panten, K., & Garg, S.
- Venue
- Journal of Diabetes Science and Technology
- Publisher
- SAGE Publications
- Published
- 2018-01-23
- Volume
- 12
- Issue
- 3
- Pages
- 680-686
- ISSN
- 1932-2968 (ISSN-L)
- OpenAlex
- W2784554518
- Cited by
- 17
- References
- 5
- FWCI
- 1.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump. https://app.cochat.ai/papers/10.1177/1932296817753644
- The paper
- Thrasher, J., Surks, H., Nowotny, I., Pierre, S., Rotthaeuser, B., Wernicke-Panten, K., & Garg, S. (2018). Safety of Insulin Lispro and a Biosimilar Insulin Lispro When Administered Through an Insulin Pump. Journal of Diabetes Science and Technology. https://doi.org/10.1177/1932296817753644
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.